In Diabetes Care, we describe how withdrawing rosiglitazone and ramipril medication affects diabetes incidence after the closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
A set of 3,366 subjects who had not developed diabetes by the end of the trial, but who had been taking double-blinded medication, were transferred to single-blinded placebo for 2 to 3 months, and their glycaemic statuses analysed.
In those allocated rosiglitazone during the trial, glycaemic status remained substantially improved, while in those that had been allocated ramipril during the trial it was modestly improved. Looking at just the washout phase, the incidence of diabetes or death was identical for those allocated to ramipril or placebo, or to rosiglitazone or placebo. In those allocated rosiglitazone or rampril, compared with those that were not allocated the respective drugs, there was also a higher incidence of normoglycaemia.
While rosiglitazone delays disease progression during treatment, the process resumes at the placebo rate when the drug is stopped.